2,321
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The role of growth hormone device optimization in patient-reported outcomes: real-world evidence from South Korea

ORCID Icon, , ORCID Icon, ORCID Icon, , , , , ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 91-106 | Received 09 Sep 2020, Accepted 10 Dec 2020, Published online: 08 Mar 2021

Figures & data

Figure 1. The conceptual model used to identify factors associated with GH device preference GH, growth hormone; GHD, growth hormone deficiency

Figure 1. The conceptual model used to identify factors associated with GH device preference GH, growth hormone; GHD, growth hormone deficiency

Table 1. Patient and caregiver/LAR demographics

Figure 2. Primary and secondary outcomes: GH device preference, satisfaction, perceived ease of use and missing fewer injections (N = 94) GH, growth hormone

Figure 2. Primary and secondary outcomes: GH device preference, satisfaction, perceived ease of use and missing fewer injections (N = 94) GH, growth hormone

Table 2. Bivariate associations between patient and caregiver/LAR characteristics and preference for Norditropin NordiFlex®

Figure 3. Associations between domains of subjective benefits and preference for (A), satisfaction with (B), perceived ease of use (C), and self-reported adherence (D) with Norditropin NordiFlex®

Figure 3. Associations between domains of subjective benefits and preference for (A), satisfaction with (B), perceived ease of use (C), and self-reported adherence (D) with Norditropin NordiFlex®

Table 3. Bivariate associations between patient and caregiver/LAR characteristics and satisfaction with Norditropin NordiFlex®

Table 4. Bivariate associations between patient and caregiver/LAR characteristics and perceived ease of use with Norditropin NordiFlex®

Table 5. Bivariate associations between patient and caregiver/LAR characteristics and self-reported adherence with Norditropin NordiFlex®

Figure 4. Forest plots of mean (95% CI) standardized scores of subjective benefits of GH device features categorized by domain: self-efficacy (A), ease of use (B), minimal disruption of daily life (C), and positive feelings about injection (D)

Figure 4. Forest plots of mean (95% CI) standardized scores of subjective benefits of GH device features categorized by domain: self-efficacy (A), ease of use (B), minimal disruption of daily life (C), and positive feelings about injection (D)
Supplemental material

ierd_a_1864324_sm9993.docx

Download MS Word (180.1 KB)

Data availability statement

The data that support the findings of this study are available on request from the corresponding author (WYC). The data contain information that could compromise research participant privacy/consent are therefore not publicly available.